Xiangyu Zhang

Xiangyu Zhang


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in Archives of Oral Biology
Verified
Journal Article
Closed access
YSYanwei Sun
Yanwei Sun
SCSijia Chen
Sijia Chen
CZChen Zhang
Chen Zhang
YLYali Liu
Yali Liu
LMLi Ma
Li Ma
XZXiangyu Zhang
Xiangyu Zhang

28 August 2022 in Molecules
Verified
Journal Article
Open access
PDF file
CYChangqing Yan
Changqing Yan
ZWZirou Wang
Zirou Wang
WLWeili Liu
Weili Liu
LPLingling Pu
Lingling Pu
RLRan Li Li
Ran Li Li
XWXinxing Wang
Xinxing Wang
Hypoxia at high-altitude leads to osteoporosis. Resveratrol (RES), as an antioxidant, has been reported to promote osteoblastogenesis and suppress osteoclastogenesis. However, the therapeutic effect of RES against osteoporosis induced by high-altitude hypoxia remains unclear. Thus, this study was intended to investigate the potential effects of RES on high-altitude hypoxia-induced osteoporosis both in vivo and in vitro. Male Wistar rats were given RES (400 mg/kg) once daily for nine weeks under hypoxia, while the control was allowed to grow under normoxia. Bone mineral density (BMD), the levels of bone metabolism-related markers, and the changes on a histological level were measured. Bone marrow-derived mesenchymal stem cells (BMSCs) and RAW264.7 were incubated with RES under hypoxia, with a control growing under normoxia, followed by the evaluation of proliferation and differentiation. The results showed that RES inhibited high-altitude hypoxia-induced reduction in BMD, enhanced alkaline phosphatase (ALP), osteocalcin (OCN), calcitonin (CT) and runt-related transcription factor 2 (RUNX2) levels, whereas it reduced cross-linked carboxy-terminal telopeptide of type I collagen (CTX-I) levels and tartrate-resistant acid phosphatase (TRAP) activity in vivo. In addition, RES attenuated histological deteriorations in the femurs. In vitro, RES promoted osteoblastogenesis and mineralization in hypoxia-exposed BMSCs, along with promotion in RUNX2, ALP, OCN and osteopontin (OPN) levels, and inhibited the proliferation and osteoclastogenesis of RAW264.7. The promotion effects of RES on osteoblastogenesis were accompanied by the down-regulation of reactive oxygen species (ROS) and hypoxia inducible factor-1α (HIF-1α) induced by hypoxia. These results demonstrate that RES can alleviate high-altitude hypoxia-induced osteoporosis via promoting osteoblastogenesis by suppressing the ROS/HIF-1α signaling pathway. Thus, we suggest that RES might be a potential treatment with minimal side effects to protect against high-altitude hypoxia-induced osteoporosis.

21 February 2020 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
XZXiangyu Zhang
Xiangyu Zhang
JYJiangkun Yan
Jiangkun Yan
HWHanxun Wang
Hanxun Wang
YWYing Wang
Ying Wang
JWJian Wang
Jian Wang
DZDongmei Zhao
Dongmei Zhao
Lysine specific demethylase 1 (LSD1) is a histone modifying enzyme, which has been proposed as a promising target for anticancer drug development. Extensive research on LSD1 inhibitors has been performed since its discovery. In order to get more information for lead identification and optimization, we carried out a molecular modeling study on a set of 43 thieno[3,2‑b]pyrrole competitive inhibitors of LSD1 using three-dimensional quantitative structure-activity relationship (3D-QSAR), molecular docking and molecular dynamics (MD) simulations. Based on the cocrystallized conformer-based alignment (CCBA) method, 3D-QSAR model of thieno[3,2‑b]pyrrole derivatives as LSD1 inhibitors was established. The significant statistics (q2= 0.595, r2= 0.959, r2pred = 0.846) of the 3D-QSAR indicated the good predictive power and statistical reliability of this model. Based on the corresponding contour maps six LSD1 inhibitors were designed and their activities were predicted by 3D-QSAR model. Meanwhile, molecular docking was performed to simulate the probable binding modes between ligands and LSD1 protein. The molecular interactions mainly contributions to the binding affinity for LSD1 inhibitions were further supplemented by 100 ns MD simulations and binding free energy calculation.

24 July 2024 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
PDF file
TLTian-Qi Li
Tian-Qi Li
YLYan Liu
Yan Liu
CFChong Feng
Chong Feng
JBJin Bai
Jin Bai
ZWZi-Rou Wang
Zi-Rou Wang
XWXinxing Wang
Xinxing Wang
To alleviate bone loss, most current drugs target osteoclasts. Saikosaponin A (Ssa), a triterpene saponin derived from Bupleurum falcatum (also known as Radix bupleuri), has immunoregulatory, neuromodulatory, antiviral, anticancer, anti-convulsant, anti-inflammatory, and anti-proliferative effects. Recently, modulation of bone homeostasis was shown to involve ferroptosis. Herein, we aimed to determine Ssa’s inhibitory effects on osteoclastogenesis and differentiation, whether ferroptosis is involved, and the underlying mechanisms. Tartrate‐resistant acid phosphatase (TRAP) staining, F‐actin staining, and pit formation assays were conducted to confirm Ssa-mediated inhibition of RANKL-induced osteoclastogenesis in vitro. Ssa could promote osteoclast ferroptosis and increase mitochondrial damage by promoting lipid peroxidation, as measured by iron quantification, FerroOrange staining, Dichloro-dihydro-fluorescein diacetate, MitoSOX, malondialdehyde, glutathione, and boron-dipyrromethene 581/591 C11 assays. Pathway analysis showed that Ssa can promote osteoclasts ferroptosis by inhibiting the Nrf2/SCL7A11/GPX4 axis. Notably, we found that the ferroptosis inhibitor ferrostatin-1 and the Nrf2 activator tert-Butylhydroquinone reversed the inhibitory effects of Ssa on RANKL-induced osteoclastogenesis. In vivo, micro-computed tomography, hematoxylin and eosin staining, TRAP staining, enzyme-linked immunosorbent assays, and immunofluorescence confirmed that in rats with periodontitis induced by lipopolysaccharide, treatment with Ssa reduced alveolar bone resorption dose-dependently. The results suggested Ssa as a promising drug to treat osteolytic diseases.

1 October 2020 in Archives of Oral Biology
Verified
Journal Article
Closed access
YLYing Liu
Ying Liu
PLPeiwen Liu
Peiwen Liu
LWLi Wang
Li Wang
YSYanfen Shi
Yanfen Shi
JCJing Chen
Jing Chen
XZXiangyu Zhang
Xiangyu Zhang

1 March 2020 in Archives of Oral Biology
Verified
Journal Article
Closed access
LMLi Ma
Li Ma
JCJing Chen
Jing Chen
HHHui Han
Hui Han
PLPeiwen Liu
Peiwen Liu
HWHuijuan Wang
Huijuan Wang
XZXiangyu Zhang
Xiangyu Zhang